Socie, G, Ritz, J, Current issues in chronic graft-versus-host disease. Blood 124 (2014), 374–384.
Pidala, J, Kurland, B, Chai, X, et al. Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. Blood 117 (2011), 4651–4657.
Choi, SW, Reddy, P, Current and emerging strategies for the prevention of graft-versus-host disease. Nat Rev Clin Oncol 11 (2014), 536–547.
Anasetti, C, Logan, BR, Lee, SJ, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med 367 (2012), 1487–1496.
Baron, F, Mohty, M, Blaise, D, et al. Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica 102 (2017), 224–234.
Soiffer, RJ, Kim, HT, McGuirk, J, et al. A prospective randomized double blind phase 3 clinical trial of anti-T lymphocyte globulin (ATLG) to assess impact on chronic graft-versus-host-disease (cGVHD) free survival in patients undergoing HLA matched unrelated myeloablative hematopoietic cell transplantation (HCT). Blood, 128, 2016, 505.
Finke, J, Schmoor, C, Bethge, WA, et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematol 4 (2017), 293–301.
Finke, J, Bethge, WA, Schmoor, C, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 10 (2009), 855–864.
Admiraal, R, Nierkens, S, de Witte, MA, et al. Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a multicentre, retrospective, pharmacodynamic cohort analysis. Lancet Haematol 4 (2017), e183–e191.
Kanakry, CG, Bolanos-Meade, J, Kasamon, YL, et al. Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide. Blood 129 (2017), 1389–1393.
